Wildeshausen

This observational study follows patients with relapsing multiple sclerosis RMS who are being treated with approved injectable or selected oral disease-modifying therapies DMTs in Germany. The study is non-interventional and open-label, designed to collect real-world data on treatment and disease progression over several years. It aims to understand how patients continue their baseline treatments and how these treatments impact various health and quality of life measures. Participants receive routine medical care with approved injectable or oral DMTs such as ofatumumab, interferon b21, glatiramer acetate, teriflunomide, dimethyl fumarate, or diroximel fumarate. The study includes two cohorts with up to approximately two years of prospective observation each, with an optional extension allowing up to four years total. Treatment decisions and monitoring follow the patients usual care and physicians discretion, including routine visits and telemedicine options. During the study, participants provide medical history, complete questionnaires, and have data collected on disability status, MRI findings, relapses, and laboratory tests. Researchers assess treatment continuation rates, fatigue, anxiety, depression, quality of life, lesion counts, and relapse rates at multiple time points. Safety and treatment interruptions are also documented. Follow-up is flexible and based on standard care procedures, with data collection occurring throughout the observational periods.

Long bone defects LBD are focal losses of bone tissue in the long bones of the arms or legs, often caused by trauma, tumors, or infections. Post-traumatic defects make up the largest group and present complex treatment challenges. This international, multicenter registry aims to collect detailed information on the prevalence, treatment methods, complications, and outcomes of post-traumatic long bone defects to improve clinical knowledge and care. Patients with long bone defects will be included from multiple centers over a 3-year period, aiming to enroll at least 600 participants. The registry will record any surgical treatments used, without dictating specific therapies, allowing individualized clinical decisions. Data collection will cover preoperative, intraoperative, and follow-up details, including the bone defect characteristics and surgical findings. Participants will undergo assessments before and during surgery, with follow-up evaluations at 6 and 12 months, or 6 months after bone healing, up to 18 months. These include functional outcomes, patient quality of life, and radiological imaging. The study will monitor patient progress and outcomes to better understand treatment effects and challenges for those with post-traumatic long bone defects.